178 filings
Page 4 of 9
8-K
87eezas01va6p
27 Jan 21
Departure of Directors or Certain Officers
4:06pm
8-K
zuk50jn
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
uw2nv59c dv212xs8
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
3h3gu1ctbq2vlatv
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
adkfn228
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
8z196vrs4wz9
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
xrrttpx
17 Sep 20
Departure of Directors or Certain Officers
7:05am
8-K
qh16ywez7h yy0ceal
15 Sep 20
Other Events
4:11pm
8-K
k5htm5wbhe5i bgralsl
14 Sep 20
Submission of Matters to a Vote of Security Holders
4:59pm
8-K
wjduv ufwzrdgeph
4 Sep 20
Entry into a Material Definitive Agreement
4:32pm
8-K
ipdbzuf
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
qy2vsld ww9
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
5q7 6u5er9
6 May 20
Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
bf8jl73ec
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
70edqu wyrp
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
pcmwr5d
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
q16ujbm8cu6t7b
13 Jan 20
Other Events
8:06am
8-K
9tdkifbdm giqkmin
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
uyacp6qbyp
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
z8ud6h4
2 Dec 19
Other Events
5:18pm